0EE0 Stock Chart & Stats
$40.60
$0.02(0.05%)
At close: 4:00 PM EDT
$40.60
$0.02(0.05%)
Day’s Range― - ―
52-Week Range$7.50 - $71.16
Previous CloseN/A
Volume4.62K
Average Volume (3M)9.64K
Market Cap
$3.53B
Enterprise Value$2.79K
Total Cash (Recent Filing)$810.34M
Total Debt (Recent Filing)$62.83M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 10, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding69,366,410
10 Day Avg. Volume2,751
30 Day Avg. Volume9,644
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$65.63Price Target Upside61.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.9
Revenue Forecast (FY)$21.95M
Bulls Say, Bears Say
Bulls Say
AMT-130 Regulatory ProgressFDA alignment materially reduces regulatory uncertainty for AMT-130 and creates a defined path toward potential approval. If successful, the program could establish a meaningful commercial foothold in Huntington’s disease.
Extended Funding RunwayThe strengthened liquidity base supports continued clinical development, confirmatory work and potential commercialization without immediate financing dependence. A runway into 2030 gives management greater flexibility to advance key programs.
Pipeline Expansion Beyond AMT-130Early AMT-260 activity broadens uniQure’s opportunity beyond Huntington’s disease and supports the value of its AAV gene-therapy platform. Higher-dose data and longer follow-up could clarify whether the signal becomes durable and reproducible.
Bears Say
Persistent Losses And Cash BurnLarge ongoing losses and negative cash generation indicate that the business has not yet achieved operating self-sufficiency. Continued investment in clinical and commercial activities may require substantial capital before products generate reliable cash flow.
AMT-191 Dose-Limiting ToxicityThe AMT-191 safety signal could delay dose optimization, reduce the usable therapeutic range or require additional monitoring and mitigation. These issues may weaken the program’s development prospects and increase execution complexity.
Limited Commercial Revenue BaseSmall and partnership-dependent revenue leaves uniQure exposed to partner execution, product uptake and milestone timing. Until wholly owned or partnered products scale materially, revenue visibility will remain limited relative to the company’s cost base.
uniQure News
0EE0 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest share price was $7.50 and its highest was $71.16 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $3.53B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.398.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.91.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 69,366,410 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 13.281%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in GB:0EE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.63 (61.64% Upside)
$65.63 (61.64% Upside)
Blogger Sentiment
Bullish
GB:0EE0 Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $966.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
156.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
0EE0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.View all GB:0EE0 earnings summaries0EE0 Stock 12 Month Forecast
Average Price Target
$65.63
▲(61.64% Upside)